News
Trademark Registration
Our trademark [思沛康] and "ONCUR'' The trademark registration certificate has been issued by the Intellectual Property Office (TIPO), Ministry of Economic Affairs
Journal Publication
International Journal of Veterinary Science (IJVS)
Published Efficacy and Safety of Para-Toluenesulfonamide in Treating Various Canine Tumors
Equine clinical trials results published at WEVA 2026
PTS Treatment for Equine Tumors to Be Presented at the World Equine Veterinary Association Congress
The clinical study results of GWA106, an investigational animal targeted tumor-ablating drug based on PTS, for the treatment of equine tumors have been accepted for presentation at the 2026 World Equine Veterinary Association (WEVA) Congress.
The abstract describing the clinical outcomes has successfully passed the WEVA scientific review process and will be presented at the congress. The findings are expected to provide valuable data regarding the safety and efficacy of PTS in the treatment of equine tumors.
The global horse population is estimated to be approximately 60 million, with around 600,000 new cases of equine tumors diagnosed each year, representing a potential therapeutic market valued at approximately USD 180 million.
However, the treatment of tumors in horses presents unique challenges. Conventional therapeutic approaches such as radiotherapy, cryotherapy, and electrochemotherapy may cause adverse effects that can interfere with essential functions including locomotion, feeding, or excretion, thereby significantly affecting the horse’s quality of life.
Surgical excision, particularly when tumors are located in specific anatomical regions, further highlights the complexities of large-animal medicine. These procedures must be performed in specialized surgical facilities designed for large animals and often require industrial-grade lifting systems to move or stabilize the horse during surgery. Such procedures impose substantial demands on infrastructure and cost, while also exposing the horse to considerable risks, including complications associated with general anesthesia and potential secondary injuries during lifting or repositioning.
In contrast, PTS therapy provides a novel and less invasive alternative. Through precise local administration and intratumoral injection, the treatment directly targets the tumor site without the need for extensive surgical intervention. This approach significantly reduces systemic burden, anesthesia-related risks, and reliance on specialized surgical facilities. As a result, PTS therapy has the potential to effectively treat tumors while preserving the horse’s mobility, comfort, and overall quality of life, addressing a critical unmet need in equine oncology.
To date, 12 horses with palpable skin tumors have been treated, including cases of melanoma, sarcoma, and squamous cell carcinoma. The related clinical outcomes will be presented at the WEVA 2026 Congress.